Eli Lilly Faces Competitive Pressure as Novo Nordisk Launches GLP-1 Pill
Eli Lilly leads the GLP-1 drug market with Mounjaro and Zepbound, but Novo Nordisk's new pill version and high valuation raise investor concerns.
Topic
Latest reporting and analysis tagged with GLP-1 drugs.
Eli Lilly leads the GLP-1 drug market with Mounjaro and Zepbound, but Novo Nordisk's new pill version and high valuation raise investor concerns.